Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies

M. H. Woo, J. J. Shuster, C. Chen, R. O. Bash, F. G. Behm, B. Camitta, C. A. Felix, B. A. Kamen, C. H. Pui, S. C. Raimondi, N. J. Winick, M. D. Amylon, M. V. Relling

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Epipodophyllotoxin-associated secondary myeloid leukemia is a devastating complication of acute lymphoblastic leukemia (ALL) therapy. The risk factors for treatment-related myeloid leukemia remain incompletely defined. Genetic deficiencies in glutathione S-transferase (GST) activities have been linked to higher frequencies of a number of human malignancies. Our objective was to determine whether the null genotype for GSTM1, GSTT1, or both, was more frequent in children with ALL who developed treatment-related myeloid malignancies as compared to those who did not. A PCR technique was used to assay for the null genotype for GSTM1 and GSTT1 in 302 children with ALL, 57 of whom also subsequently developed treatment-related acute myeloid leukemia or myelodysplastic syndrome. Among children with ALL who did not develop treatment-related myeloid malignancies, the frequencies of GSTM1 and GSTT1 wild-type, GSTM1 null-GSTT1 wild-type, GSTM1 wild type-GSTT1 null, and GSTM1 and GSTT1 null genotypes were 40%, 42%, 9% and 9%, respectively. The corresponding frequencies for patients who developed acute myeloid malignancies were 42%, 32%, 11% and 16%, respectively (P = 0.26). A statistically significant increase in the frequency of the GST null genotype was observed in male patients who developed myeloid malignancies as compared to male ALL control patients (P = 0.036), but was not observed in female patients (P = 0.51). Moreover, a logistic regression analysis of possible predictors for myeloid malignancies, controlling for gender and race, did not reveal an association of GSTM1 or GSTT1 null genotypes (P = 0.62 and 0.11, respectively) with treatment-related malignancies. Our data suggest that GSTM1 and GSTT1 null genotypes may not predispose to epipodophyllotoxin-associated myeloid malignancies.

Original languageEnglish (US)
Pages (from-to)232-237
Number of pages6
JournalLeukemia
Volume14
Issue number2
StatePublished - 2000

Fingerprint

Glutathione Transferase
Genotype
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms
Podophyllotoxin
Myeloid Leukemia
Therapeutics
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Logistic Models
Regression Analysis
Polymerase Chain Reaction

Keywords

  • Acute myeloid leukemia
  • Epipodophyllotoxins
  • Glutathione S-transferase genotype
  • GSTM1
  • GSTT1

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Woo, M. H., Shuster, J. J., Chen, C., Bash, R. O., Behm, F. G., Camitta, B., ... Relling, M. V. (2000). Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia, 14(2), 232-237.

Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. / Woo, M. H.; Shuster, J. J.; Chen, C.; Bash, R. O.; Behm, F. G.; Camitta, B.; Felix, C. A.; Kamen, B. A.; Pui, C. H.; Raimondi, S. C.; Winick, N. J.; Amylon, M. D.; Relling, M. V.

In: Leukemia, Vol. 14, No. 2, 2000, p. 232-237.

Research output: Contribution to journalArticle

Woo, MH, Shuster, JJ, Chen, C, Bash, RO, Behm, FG, Camitta, B, Felix, CA, Kamen, BA, Pui, CH, Raimondi, SC, Winick, NJ, Amylon, MD & Relling, MV 2000, 'Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies', Leukemia, vol. 14, no. 2, pp. 232-237.
Woo MH, Shuster JJ, Chen C, Bash RO, Behm FG, Camitta B et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia. 2000;14(2):232-237.
Woo, M. H. ; Shuster, J. J. ; Chen, C. ; Bash, R. O. ; Behm, F. G. ; Camitta, B. ; Felix, C. A. ; Kamen, B. A. ; Pui, C. H. ; Raimondi, S. C. ; Winick, N. J. ; Amylon, M. D. ; Relling, M. V. / Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. In: Leukemia. 2000 ; Vol. 14, No. 2. pp. 232-237.
@article{e7a471e6be964fd28e7b2697177dfb05,
title = "Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies",
abstract = "Epipodophyllotoxin-associated secondary myeloid leukemia is a devastating complication of acute lymphoblastic leukemia (ALL) therapy. The risk factors for treatment-related myeloid leukemia remain incompletely defined. Genetic deficiencies in glutathione S-transferase (GST) activities have been linked to higher frequencies of a number of human malignancies. Our objective was to determine whether the null genotype for GSTM1, GSTT1, or both, was more frequent in children with ALL who developed treatment-related myeloid malignancies as compared to those who did not. A PCR technique was used to assay for the null genotype for GSTM1 and GSTT1 in 302 children with ALL, 57 of whom also subsequently developed treatment-related acute myeloid leukemia or myelodysplastic syndrome. Among children with ALL who did not develop treatment-related myeloid malignancies, the frequencies of GSTM1 and GSTT1 wild-type, GSTM1 null-GSTT1 wild-type, GSTM1 wild type-GSTT1 null, and GSTM1 and GSTT1 null genotypes were 40{\%}, 42{\%}, 9{\%} and 9{\%}, respectively. The corresponding frequencies for patients who developed acute myeloid malignancies were 42{\%}, 32{\%}, 11{\%} and 16{\%}, respectively (P = 0.26). A statistically significant increase in the frequency of the GST null genotype was observed in male patients who developed myeloid malignancies as compared to male ALL control patients (P = 0.036), but was not observed in female patients (P = 0.51). Moreover, a logistic regression analysis of possible predictors for myeloid malignancies, controlling for gender and race, did not reveal an association of GSTM1 or GSTT1 null genotypes (P = 0.62 and 0.11, respectively) with treatment-related malignancies. Our data suggest that GSTM1 and GSTT1 null genotypes may not predispose to epipodophyllotoxin-associated myeloid malignancies.",
keywords = "Acute myeloid leukemia, Epipodophyllotoxins, Glutathione S-transferase genotype, GSTM1, GSTT1",
author = "Woo, {M. H.} and Shuster, {J. J.} and C. Chen and Bash, {R. O.} and Behm, {F. G.} and B. Camitta and Felix, {C. A.} and Kamen, {B. A.} and Pui, {C. H.} and Raimondi, {S. C.} and Winick, {N. J.} and Amylon, {M. D.} and Relling, {M. V.}",
year = "2000",
language = "English (US)",
volume = "14",
pages = "232--237",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies

AU - Woo, M. H.

AU - Shuster, J. J.

AU - Chen, C.

AU - Bash, R. O.

AU - Behm, F. G.

AU - Camitta, B.

AU - Felix, C. A.

AU - Kamen, B. A.

AU - Pui, C. H.

AU - Raimondi, S. C.

AU - Winick, N. J.

AU - Amylon, M. D.

AU - Relling, M. V.

PY - 2000

Y1 - 2000

N2 - Epipodophyllotoxin-associated secondary myeloid leukemia is a devastating complication of acute lymphoblastic leukemia (ALL) therapy. The risk factors for treatment-related myeloid leukemia remain incompletely defined. Genetic deficiencies in glutathione S-transferase (GST) activities have been linked to higher frequencies of a number of human malignancies. Our objective was to determine whether the null genotype for GSTM1, GSTT1, or both, was more frequent in children with ALL who developed treatment-related myeloid malignancies as compared to those who did not. A PCR technique was used to assay for the null genotype for GSTM1 and GSTT1 in 302 children with ALL, 57 of whom also subsequently developed treatment-related acute myeloid leukemia or myelodysplastic syndrome. Among children with ALL who did not develop treatment-related myeloid malignancies, the frequencies of GSTM1 and GSTT1 wild-type, GSTM1 null-GSTT1 wild-type, GSTM1 wild type-GSTT1 null, and GSTM1 and GSTT1 null genotypes were 40%, 42%, 9% and 9%, respectively. The corresponding frequencies for patients who developed acute myeloid malignancies were 42%, 32%, 11% and 16%, respectively (P = 0.26). A statistically significant increase in the frequency of the GST null genotype was observed in male patients who developed myeloid malignancies as compared to male ALL control patients (P = 0.036), but was not observed in female patients (P = 0.51). Moreover, a logistic regression analysis of possible predictors for myeloid malignancies, controlling for gender and race, did not reveal an association of GSTM1 or GSTT1 null genotypes (P = 0.62 and 0.11, respectively) with treatment-related malignancies. Our data suggest that GSTM1 and GSTT1 null genotypes may not predispose to epipodophyllotoxin-associated myeloid malignancies.

AB - Epipodophyllotoxin-associated secondary myeloid leukemia is a devastating complication of acute lymphoblastic leukemia (ALL) therapy. The risk factors for treatment-related myeloid leukemia remain incompletely defined. Genetic deficiencies in glutathione S-transferase (GST) activities have been linked to higher frequencies of a number of human malignancies. Our objective was to determine whether the null genotype for GSTM1, GSTT1, or both, was more frequent in children with ALL who developed treatment-related myeloid malignancies as compared to those who did not. A PCR technique was used to assay for the null genotype for GSTM1 and GSTT1 in 302 children with ALL, 57 of whom also subsequently developed treatment-related acute myeloid leukemia or myelodysplastic syndrome. Among children with ALL who did not develop treatment-related myeloid malignancies, the frequencies of GSTM1 and GSTT1 wild-type, GSTM1 null-GSTT1 wild-type, GSTM1 wild type-GSTT1 null, and GSTM1 and GSTT1 null genotypes were 40%, 42%, 9% and 9%, respectively. The corresponding frequencies for patients who developed acute myeloid malignancies were 42%, 32%, 11% and 16%, respectively (P = 0.26). A statistically significant increase in the frequency of the GST null genotype was observed in male patients who developed myeloid malignancies as compared to male ALL control patients (P = 0.036), but was not observed in female patients (P = 0.51). Moreover, a logistic regression analysis of possible predictors for myeloid malignancies, controlling for gender and race, did not reveal an association of GSTM1 or GSTT1 null genotypes (P = 0.62 and 0.11, respectively) with treatment-related malignancies. Our data suggest that GSTM1 and GSTT1 null genotypes may not predispose to epipodophyllotoxin-associated myeloid malignancies.

KW - Acute myeloid leukemia

KW - Epipodophyllotoxins

KW - Glutathione S-transferase genotype

KW - GSTM1

KW - GSTT1

UR - http://www.scopus.com/inward/record.url?scp=0033954510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033954510&partnerID=8YFLogxK

M3 - Article

C2 - 10673738

AN - SCOPUS:0033954510

VL - 14

SP - 232

EP - 237

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -